• / Free eNewsletters & Magazine
  • / My Account

NN

  1. NN , Inc. Announces Quarterly Dividend

    NN , Inc. Announces Quarterly Dividend

  2. Phase 2 COSMOS Study Results Published in The Lancet Demonstrate Efficacy and Safety of Janssen’s Once-Daily Simeprevir in All Oral 12-Week Combination with Sofosbuvir for Genotype 1 Chronic ...

    Phase 2 COSMOS Study Results Published in The Lancet Demonstrate Efficacy and Safety of Janssen’s Once-Daily Simeprevir in All Oral 12-Week Combination with Sofosbuvir for Genotype 1 Chronic Hepatitis C

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.